Navigation Links
Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test
Date:1/15/2014

Westlake Village, Calif. (PRWEB) January 15, 2014

Cynvenio, a cancer diagnostics company focused on transforming cancer treatment and management through the genomic analysis of tumor cells in the bloodstream, today announced that it will offer Therapy Finder™, a web-based cancer decision support application powered by CollabRx, Inc.

Available as a reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast cancer patients and their physicians with a dynamic resource to navigate and understand both the current standard of care as well as cutting edge experimental therapy options with the goal of enabling patients to receive the best possible care. ClearID customers will gain access to focused news and patient-oriented educational material on advances in breast cancer, the latest medical and scientific research, risk factors for recurrence, monitoring, and early detection. The breast cancer Therapy Finder is dynamically updated and curated by CollabRx medical and scientific personnel with the support of an editorial board composed of independent breast cancer clinical experts. The Therapy Finder for Breast Cancer is the most recent electronic decision support application released by CollabRx and complements existing Therapy Finders for lung cancer, colorectal cancer, and melanoma. It is the first such app developed specifically for a patient user.

ClearID is Cynvenio’s monitoring test for breast cancer survivors at high risk of disease recurrence. It analyzes DNA from tumor cells in the bloodstream for cancer-associated genomic mutations which can be used to characterize disease status and available treatment options. Through the partnership with CollabRx, clinicians and researchers ordering ClearID tests from Cynvenio will also have the option of requesting genomic reporting via the Genetic Variant Annotation (GVA) ServiceTM which provides clinically actionable and dynamically updated data.

“This collaboration will directly benefit breast cancer patients, survivors and their physicians by providing them with two powerful integrated tools,” said André de Fusco, Cynvenio’s CEO. “The ClearID Breast Cancer test offers genomic insights from a standard blood draw analyzed by next gen sequencing. By pairing ClearID with the CollabRx Therapy Finder we can now take into account an individual patient’s molecular (tumor) data when offering the latest insights into breast cancer treatments. This is a milestone in our efforts to provide individualized breast cancer screening and surveillance.”

“The CollabRx Therapy Finder for breast cancer provides patients with an up-to-date and easily accessible tool to navigate therapy considerations that incorporate molecular data and also receive curated news that pertains to their disease,” said Thomas Mika, Chairman, President & CEO of CollabRx. “We are excited to collaborate with Cynvenio on its introduction with the goal of providing metastatic breast cancer patients with an easy to use tool to aid in treatment planning by contexualizing the state of scientific and medical research backed by sound science.”

The companion announcement from CollabRx is available on: http://www.collabrx.com.

About Cynvenio Biosystems, Inc.

Cynvenio is a cancer diagnostics company focused on transforming cancer treatment and management through the molecular analysis of tumor biomarkers in the bloodstream. This expertise has resulted in two distinct product offerings: ClearID Breast Cancer monitoring program and LiquidBiopsy. ClearID Breast Cancer, designed for use by patients and their physicians, is a cancer detection and monitoring program that assesses 50 oncogenes for more than 4,500 genetic mutations using next-generation sequencing. This test and real-time molecular analysis provide actionable information that can inform treatment considerations and help improve treatment outcomes. LiquidBiopsy is designed for industry and academic researchers to identify the presence of tumor-cell genetic mutations in whole blood. Founded in 2008, Cynvenio is headquartered in Westlake Village, Calif. (Los Angeles). For more information visit http://www.cynvenio.com.

LiquidBiopsy® is a registered trademark of Cynvenio Biosystems, Inc.

About CollabRx

CollabRx, Inc. is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.

Read the full story at http://www.prweb.com/releases/2014/01/prweb11490878.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Cynvenio Biosystems to Present Clinical Data on Mutational Analysis of LiquidBiopsy® Tumor Samples at the 2013 ASCO Annual Meeting
2. Cynvenio Biosystems Receives CLIA Certification for its Genomic Sequencing Laboratory
3. Cynvenio and CollabRx Announce Partnership for Cancer Molecular Diagnostics
4. Fortis Offers Bachelor of Science in Nursing Degree Program to Florida Students
5. Gundersen Lutheran Offers Heart Surgery with Less Pain, Faster Recovery
6. UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
7. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
8. Big Saver: Molderizer Offers 30% Mold Remediation Products Price Cut
9. Tri-Valley Sedation Dentist Dr. Endre Selmeczy Now Offers High-quality Dental Restorations
10. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
11. Salimetrics Offers New Saliva Collection Aid for Easy Collection of Passive Drool Samples
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... BALTIMORE, Md. (PRWEB) , ... October 11, 2017 ... ... for digital pathology, announced today it will be hosting a Webinar titled, “Pathology ... of  Advanced Pathology Associates , on digital pathology adoption best practices and how ...
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
(Date:10/10/2017)... , ... October 10, 2017 , ... San Diego-based team ... its corporate rebranding initiative announced today. The bold new look is part of ... the company moves into a significant growth period. , It will also expand its ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
Breaking Biology News(10 mins):